Analysts were forecasting $5bn in peak sales for Evacetrapib. LLY shares are down 7%-8% today, which implies that Evacetrapib was being valued at c.USD$7bn / CAD$9bn while still only in PIII.

I wish one of these analysts would start looking at RVX!

And MRK's Anacetrapib PIII is running until 2017. An interim analysis will be done at the end of this year. Remember how RVX got slammed when MRK released the results of its last trial (with the good HDL results).

The thing that I find really ironic is that LLY and MRK have 'got away' with running trials with what looks like 5 point MACE i.e. it includes revascularization...